Novo Nordisk said its experimental drug CagriSema demonstrated a weight‑loss advantage over tirzepatide in recent trials.
Further specifics about the study were not immediately available.
Novo Nordisk's CagriSema shows weight loss edge over tirzepatide in trials
Novo Nordisk reported that its experimental drug CagriSema achieved greater weight loss than tirzepatide in clinical trials.
HV
Helena Vásquez · Business Desk · 21 Sept 2026 · 22:27 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
HV
Written by
Helena Vásquez
Business Desk
Helena covers corporate news for listed and private companies across Europe, from strategy shifts to leadership changes, with an eye for what a story signals about the broader market.
More from Helena Vásquez →
